text:
EX-99.2
3
fsnn_ex992.htm
PRESS RELEASE
fsnn_ex992.htm
Exhibit 99.2
Fusion Closes on Approximately $44.0 Million of Financing
Enables Acquisition of Cloud Services Business
NEW YORK, January 6, 2014
- - Fusion (OTCQB: FSNN), an emerging leader in the cloud services market, today announced that on December 31, 2013, it closed several financing transactions aggregating to approximately $44.0 million, comprised of approximately $18.5 million in equity, and $25.5 million in term debt.
Fusion raised approximately $18.5 million through a private placement of investment units consisting of Convertible Preferred Securities and Warrants to accredited investors, including all members of Fusion's Board of Directors and members of its Advisory Board. As part of the capital raised in the offering, Matthew Rosen, Fusion's Chief Executive Officer and Marvin Rosen, Fusion's Chairman, exchanged $2.05 million of Company obligations for the investment units sold in the private placement. Fusion received net cash proceeds in the private placement, after giving effect to transaction expenses, of approximately $15.6 million.
Aegis Capital Corp. served as lead placement agent.
In addition to the equity, Fusion raised $25.5 million through the issuance of 5-year senior notes to Praesidian Capital and Plexus Capital, Fusion's existing lenders.
The Company's aggregate net proceeds from these financing transactions was $40.5 million, $32.1 million of which was used to fund its acquisition of the cloud services assets of Broadvox's business services division, with the remainder to be used for acquisition transaction expenses, to advance sales and marketing efforts, and for general corporate purposes. The Broadvox cloud services unit will be integrated into NBS, Fusion's cloud services division. NBS was acquired in October, 2012, and fully integrated by the end of the first quarter of 2013. The addition of NBS' proprietary platform and infrastructure has accelerated Fusion's organic growth and enabled the Company to effectively integrate the current acquisition of Broadvox's cloud services, as well as facilitate future accretive acquisitions.
"The strong support we received in the financing from new and existing shareholders, Directors, Advisory Board members, and from financial partners such as Praesidian Capital, Plexus Capital, and several other notable institutions and individuals, reaffirms our confidence that we have the right strategy for growth", said Matthew Rosen, Fusion's Chief Executive Officer. "This financing advances our cloud services strategy with an acquisition that will allow us to rapidly scale, accelerate our organic growth and effectively plan for additional strategic acquisitions as we emerge as a leading provider in the cloud services marketplace", continued Mr. Rosen.
1
Commenting on the transaction, Glenn C. Harrison, Managing Director of Praesidian, said, "Since our initial investment, we have become very familiar with the talented Fusion management team through this acquisition as well as their acquisition of NBS last year, and have found them to be both innovative and experienced. Their success at meeting key goals in 2013 confirms our confidence in what we believe to be a winning strategy and plan".
Expanding on Mr. Harrison's comments, Mike Becker, co-founder and Partner of Plexus, said, "We believe this financing strongly reflects our commitment to support Fusion in the execution of its strategy".
Further details of the equity financing are contained in Fusion's Current Report on Form 8-K filed today with the SEC.
About Fusion
Fusion is a leading provider of integrated cloud solutions to small, medium and large businesses. Fusion's advanced, proprietary service platform enables the integration of leading edge solutions in the cloud, including cloud voice, cloud connectivity, cloud storage and security. Fusion's innovative yet proven cloud solutions lower our customers' cost of ownership, and deliver new levels of security, flexibility, scalability and speed of deployment. For more information, please visit www.fusiontel.com.
About Praesidian
Praesidian Capital partners with small and mid-sized businesses by providing private debt capital. With a focus on its core competency in mezzanine financing, Praesidian invests in established, historically profitable companies often in connection with a management/leveraged buyout, recapitalization or refinancing. Based in New York City, Praesidian manages more than $700 million in committed capital. For more information, visit www.praesidian.com.
About Plexus
With offices in Charlotte and Raleigh, North Carolina, Plexus manages $255 million and invests in middle market, high growth companies located in the United States. Plexus' capital is most often used to fund growth, acquisitions, leveraged buyouts, management buyouts, and stock repurchases. Prospective portfolio companies have strong management teams, positive cash flow, large market opportunities, and need capital to execute their business plans.
Forward Looking Statements:
Statements in this press release that are not purely historical facts, including statements regarding Fusion's beliefs, expectations, intentions or strategies for the future, may be "forward-looking statements" under the Private Securities Litigation Reform Act of 1996. Such statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as "may", "expect", "anticipate", "intend", "estimate" or "continue" or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward-looking statements are speculative, and there are certain risks and uncertainties that could cause actual events or results to differ from those referred to in such forward-looking statements. This disclosure highlights some of the important risks regarding the Company's business. The primary risk of the Company is its ability to raise new and continued capital to execute its comprehensive business strategy. There may be additional risks associated with the integration of businesses following an acquisition, concentration of revenue from one source, competitors with broader product lines and greater resources, emergence into new markets, the termination of any of the Company's significant contracts or partnerships, the Company's ability to comply with its senior debt agreements, the Company's inability to maintain working capital requirements to fund future operations or the Company's ability to attract and retain highly qualified management, technical and sales personnel and the other factors identified by us from time to time in the Company's filings with the Securities and Exchange Commission, which are available through http://www.sec.gov. However, the risks included should not be assumed to be the only things that could affect future performance. We may, among other things, also be subject to service disruptions, delays in collections, or facilities closures caused by potential or actual acts of terrorism or government security concerns.
Fusion Contact
Laura Nadal, 212-389-9720
lnadal@fusiontel.com
2

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Aegis Capital Corp.

text: Fusion

text: Fusion

text: Broadvox

text: Broadvox cloud services unit

text: Fusion

text: Fusion

text: Broadvox

text: Fusion

text: Glenn C. Harrison

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion

text: Fusion


dataset: buster

text:
EX-99.3
2
tm2115487d1_ex99-3.htm
EXHIBIT 99.3
Exhibit 99.3
Inotiv, Inc. Announces Debt Financing
and Completion of Acquisitions of HistoTox Labs, Inc. and Bolder BioPATH, Inc.
WEST LAFAYETTE, IN
, April 30, 2021 -
Inotiv, Inc. (NASDAQ:NOTV) (the "Company", "We", "Our" or "Inotiv")
, a leading
contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that
the Company has secured $28.0 million in debt financing from First Internet Bank of Indiana and completed the previously-announced acquisition
of substantially all of the assets of HistoTox Labs, Inc. ("HistoTox Labs") and the acquisition by merger of Bolder BioPATH,
Inc. ("Bolder BioPATH"), effective April 30, 2021.
The aggregate consideration paid for substantially
all of the assets of HistoTox Labs consisted of $22.0 million in cash and the assumption of certain specified liabilities of the seller.
The aggregate consideration paid to the shareholders
of Bolder BioPATH in the merger consisted of $18.5 million in cash, 1,588,235 Inotiv common shares, and $1.5 million in subordinated notes.
"These strategic acquisitions expand our
nonclinical pharmacology and histopathology services and augment and extend the effective range of our services from early discovery through
preclinical development", said Robert Leasure, Jr., Inotiv's President and Chief Executive Officer. "This will
increase the breadth of discovery pharmacology models that we can offer clients pursuing traditional oral small molecule therapies to
next generation injectables and gene therapies. By combining these acquisitions with our planned expansion and investments, we are positioned
to offer comprehensive laboratory solutions in DMPK and cell & molecular biology, immunohistochemistry and histopathology to clients
pursuing preclinical drug safety and efficacy programs".
A Current Report on Form 8-K containing further
details regarding the debt financing will be filed by Inotiv and made available on the U.S. Securities and Exchange Commission's
EDGAR website.
About the Company
Inotiv, Inc. is a pharmaceutical development
company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading
drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its
clients' discovery and development objectives for improved decision-making and accelerated goal attainment. The
Company's products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit
inotivco.com
for more information about the Company.
This release may contain forward-looking statements
that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and
demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and
regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the
impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken
by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties and various
other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
Company Contact
Investor Relations
Inotiv, Inc.
The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer
Kalle Ahl, CFA
(765) 497-8381
(212) 836-9614
btaylor@inotivco.com
kahl@equityny.com
Devin Sullivan
(212) 836-9608
dsullivan@equityny.com

label: organization

text: Inotiv, Inc.

text: HistoTox Labs, Inc.

text: Bolder BioPATH, Inc.

text: Inotiv, Inc.

text: HistoTox Labs, Inc.

text: Bolder BioPATH

text: Bolder BioPATH

text: Bolder BioPATH

text: Inotiv, Inc.

text: Inotiv, Inc.

label: person

text: Beth A. Taylor

source_dataset: expertai/BUSTER

annotation_scope: BUSTER company-role spans plus reviewed organization, fund, person, and event additions with document-local surface projection; annotations remain non-exhaustive


text:
EX-99.1
6
a05-15805_1ex99d1.htm
EX-99.1
Exhibit
99.1
FOR IMMEDIATE RELEASE
Contact:
Gregg Peters
952-944-5600
investor_relations@dept56.com
DEPARTMENT
56 ANNOUNCES CLOSING OF
ACQUISITION
OF LENOX, INC.
EDEN PRAIRIE, Minn., September 1, 2005 - Department
56, Inc. (NYSE: DFS), a leading collectible and giftware company, today
announced the closing of its acquisition of Lenox, Incorporated, from
Brown-Forman Corp. (NYSE: BFB) for approximately $196.5 million in cash which
includes a $6.5 million estimated working capital adjustment to the purchase
price which will be finalized after closing.
Lenox, which generated net sales of approximately
$465 million in its most recent fiscal year (ended April 30, 2005), is a
leading tabletop, collectible and giftware company. They market fine china, crystal, silver and
flatware products under the Lenox, Dansk and Gorham brand names. These products are sold primarily through
department and specialty stores, owned retail outlet stores and
direct-to-the-consumer through catalogs, direct mail and the Internet.
Department 56 has financed the acquisition through
new credit facilities arranged through UBS Securities LLC.
About Department 56
Department 56, Inc. is a leading collectible
and giftware company that recognizes the importance of celebrating life's
extraordinary moments - holidays, special days, and every day. Best known for
its lighted Village buildings, Snowbabies™ figurines and extensive holiday and
special occasion product lines, the Company designs and develops festive
giftware with the highest principles of quality and creativity.
Department 56 sells its products through
approximately 12,500 wholesale customers who operate gift, specialty and
department store locations in the United States and Canada, Company-operated
retail stores, direct mail catalog companies and international distributors.
Through its Time to Celebrate™ division, the Company sells holiday and seasonal
giftware assortments direct to consumers at home shows. Time to Celebrate had
approximately 1,000 independent sales consultants at the end of 2004.
Forward-Looking Statements
This press release contains forward-looking
statements about the Company's performance based on management's current
expectations and assumptions and are not guarantees of future performance. Any
conclusions or expectations expressed in, or drawn from, the statements in this
press release concerning matters that are not historical corporate financial
results are forward-looking statements that involve risks and uncertainties.
Actual results may differ materially from forward-looking statements and the assumptions
on which they are based. Such statements reflect management's current
expectations or beliefs, and are subject to risks and uncertainties that could
cause actual results or events to vary from stated expectations, which
variations could be material and adverse. Factors that could produce such
a variation include, but are
not limited to, the
following: the risks and uncertainties associated with successfully
integrating Department 56, Inc. and Lenox, Inc.; the ability to retain key
personnel; the inherent unreliability of earnings, revenue and cash flow
predictions due to numerous factors, many of which are beyond the Company's
control; developments in the demand for each companies' products and services;
relationships with major customers and suppliers; unanticipated delays, costs
and expenses inherent in the development and marketing of new products and
services; the impact of governmental laws and regulations; and competitive
factors. The Company undertakes no obligation to update or publish in the
future any forward-looking statements. Also, please read the bases, assumptions
and factors set out in Item 7 in the Company's Form 10-K for 2004 dated
March 17, 2005, and filed under the Securities Exchange Act of 1934
# # #

text:
DEPARTMENT
56

text: LENOX, INC.

text:
Department
56, Inc.

text: Lenox

text: Brown-Forman Corp.

text: Lenox

text: Lenox

text: Department 56

text: Department 56

text: Department 56, Inc.

text: Department 56

text: Department 56, Inc.

text: Lenox, Inc.


text:
EX-99
2
pressrls.txt
Exhibit 99.1
1-800-FLOWERS.COM(R) Closes Acquisition
of Fannie May Confections Brands, Inc., a Multi-Channel Retailer and
Manufacturer of Leading Confectionery Brands Including: Fannie May(R), Harry
London(R) and Fanny Farmer(R)
CARLE PLACE, N.Y.--(BUSINESS WIRE)--May 2, 2006--
Acquisition Expected to Increase Company's Fiscal 2007 Revenues in the Fast
Growing Food, Wine and Gift Basket Category to More Than $200 Million
1-800-FLOWERS.COM (NASDAQ: FLWS), a leading multi-channel retailer of thoughtful
gifts for all occasions, today announced the closing of its acquisition of
Fannie May Confections Brands, Inc., a multi-channel retailer and manufacturer
of chocolate and other confections under the well-known Fannie May, Harry London
and Fanny Farmer brands. The acquisition, for approximately $85 million in cash,
includes a modern 200,000-square-foot candy manufacturing facility in North
Canton, Ohio and 52 Fannie May retail stores in the Chicago area, where the
chocolate brand has been a tradition since 1920. Fannie May Confections Brands,
Inc. generated revenues of approximately $75 million in its most recent fiscal
year ended April 30, 2006.
Jim McCann, CEO of 1-800-FLOWERS.COM, said, "This acquisition significantly
expands our position in the key Food, Wine and Gift Basket category where we are
rapidly becoming a leading player. The Fannie May, Harry London and Fanny Farmer
names represent premium chocolate brands with a history of very strong customer
loyalty. These brands offer a significant opportunity for growth, particularly
through the leveraging of our assets and capabilities in the online and direct
marketing space as well as into our Bloomnet florist network. The acquisition
also brings an experienced and focused management team that can help us grow our
business in this important gifting area".
The Company said the acquisition is being financed with a bank debt and cash on
hand. In its most recent release of its fiscal 2006 third quarter results, the
Company said that it expects the financial impact of the acquisition, including
operating losses associated with the seasonality of the Fannie May Confections
Brands business, and interest expense associated with the debt financing being
used, will reduce the Company's fiscal 2006 fourth quarter earnings by
approximately $0.02-$0.03 per share. The Company said it expects the acquisition
will be accretive to earnings per share in Fiscal 2007.
David Taiclet, CEO of Fannie May Confections Brands, said "We are very excited
to be joining the 1-800-FLOWERS.COM team. We now we have the opportunity to
leverage 1-800-FLOWERS.COM's unique collection of assets, including its more
than 15 million customers, its leading online and direct-to-consumer marketing
capabilities and its multi-channel fulfillment systems to accelerate the growth
of our great confection brands on a national basis".
About Fannie May Confections Brands, Inc.
The Harry London brand was purchased in 2003 and the Fannie May and Fanny Farmer
brands in 2004 by Alpine Confections, Inc., (subsequently renamed Fannie May
Confections Brands, Inc.) Alpine Confections, Inc. was named the Candy Industry
2005 Manufacturer of the Year by Candy Industry Magazine in recognition of its
growth and achievements in the marketplace.
About 1-800-FLOWERS.COM(R) For more than 30 years, 1-800-FLOWERS.COM Inc. -
"Your Florist of choice(sm)" - has been providing customers around the world
with the freshest flowers and finest selection of plants, gift baskets, gourmet
foods and confections, and plush stuffed animals perfect for every occasion.
1-800-FLOWERS.COM(R) offers the best of both worlds: exquisite, florist-designed
arrangements individually created by some of the nation's top floral artists and
hand-delivered the same day, and spectacular flowers shipped from our growers to
your door fresh. Customers can shop 1-800-FLOWERS.COM 24 hours a day, 7 days a
week via the phone or Internet(1-800-356-9377 or www.1800flowers.com) or by
visiting a Company-operated or franchised store. Sales and Service Specialists
are available 24/7, and fast and reliable delivery is offered same day, any day.
As always, 100 percent satisfaction and freshness is guaranteed. The
1-800-FLOWERS.COM collection of brands also includes home decor and garden
merchandise from Plow & Hearth(R) (1-800-627-1712 or www.plowandhearth.com);
popcorn and specialty treats from The Popcorn Factory(R) (1-800-541-2676 or
www.thepopcornfactory.com); exceptional cookies and baked gifts from
Cheryl&Co.(R) (1-800-443-8124 or wwwcherylandco.com); premium chocolates and
confections from Fannie May Confections Brands(R) (www.fanniemay.com and
www.harrylondon.com); gourmet foods from GreatFood.com(R) (www.greatfood.com);
children's gifts from HearthSong(R) (www.hearthsong.com) and Magic Cabin(R)
(www.magiccabin.com) and wine gifts from the WineTasting Network(R)
(www.ambrosiawine.com and www.winetasting.com). 1-800-FLOWERS.COM, Inc. stock is
traded on the NASDAQ market under ticker symbol FLWS.
Special Note Regarding Forward-Looking Statements:
A number of statements contained in this press release, other than statements of
historical fact, are forward-looking within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements involve risks and
uncertainties that could cause actual results to differ materially from those
expressed or implied in the applicable statements. These risks and uncertainties
include, but are not limited to: the Company's ability to successfully integrate
Fannie May Confections Brands; its ability to achieve forecasted revenue growth,
enhanced profitability and other synergistic benefits, including its ability to
grow its Food, Wine and Gift Basket revenues to more than $200 million in fiscal
2007; its ability to maintain and enhance its online shopping web sites to
attract customers; its ability to successfully introduce new products and
product categories; its ability to provide timely fulfillment of customer
orders; its ability to cost effectively acquire and retain customers; its
ability to compete against existing and new competitors; its ability to cost
efficiently manage inventories and general consumer sentiment and economic
conditions that may affect levels of discretionary customer purchases of the
Company's products. For a more detailed description of these and other risk
factors, please refer to the Company's SEC filings including the Company's
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company
expressly disclaims any intent or obligation to update any of the forward
looking statements made in this release or in any of its SEC filings except as
may be otherwise stated by the Company.
CONTACT: 1-800-FLOWERS.COM
Investor: Joseph D. Pititto, 516-237-6131
invest@1800flowers.com
or
Media:
Steven Jarmon, 516-237-4675
sjarmon@1800flowers.com
SOURCE: 1-800-FLOWERS.COM Inc.

text: FLOWERS.COM

text: Fannie May Confections Brands, Inc.

text: FLOWERS.COM

text: Fannie May Confections Brands, Inc.

text:
Fannie May Confections Brands,
Inc.

text: David Taiclet

text: Fannie May Confections Brands, Inc.

text:
Fannie May
Confections Brands, Inc.


text:
EX-99.1
10
ea137380ex99-1_planetgreen.htm
PRESS RELEASE, DATED MARCH 9, 2021
Exhibit 99.1
Planet Green Holdings Corp. Enters Into
Share Exchange Agreement
New York, NY., March 9, 2021 /PRNewswire/-- Planet Green Holdings
Corp. (the "Company") (NYSE American: PLAG) announced today that on March 9, 2021, the Company has entered into a Share
Exchange Agreement with Jilin Chuangyuan Chemical Co., Ltd. ("Target") and each shareholder of the Target (collectively
"Sellers"). Pursuant to the Share Exchange Agreement, the Company will acquire 75% of outstanding equity interests of
the Target, a company that researches, develops and manufactures formaldehyde, urea formaldehyde adhesive, methylal and clean fuel
products and sells such products in China.
Pursuant to the Share Exchange Agreement, the company will issue
3,300,000 shares of common stock of the Company to the Sellers in exchange for the transfer of 75% of the equity interest of the
Target. The transaction is subject to closing conditions that are customary for transactions of this type.
Forward Looking Statements
This news release contains "forward-looking statements"
within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate",
"plan", "outlook", and "project" and other similar expressions that indicate future events or trends
or are not statements of historical matters. These statements are based on our management's current expectations and beliefs, as
well as a number of assumptions concerning future events.
Such forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other important factors, many of which are outside of our control and all of which could
cause actual results to differ materially from the results discussed in the forward-looking statements. Accordingly, forward-looking
statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation
to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new
information, future events or otherwise, except as may be required under applicable securities laws. Factors that could cause actual
results to differ materially from those expressed or implied in forward-looking statements can be found in our reports filed with
the Securities and Exchange Commission, which are available, free of charge, on the SEC's website at www.sec.gov.
For more information please contact:
Ms. Lili Hu
Chief Financial Officer
Phone: 718 799 0380
Email:
hulili@planetgreenholdings.com

text: Planet Green Holdings Corp.

text:
Planet Green Holdings
Corp.

text: Jilin Chuangyuan Chemical Co., Ltd.

text: Lili Hu


text:
EX-99
3
ex99_1form8k-071305.txt
EXHIBIT 99.1
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
JULY 11, 2005
INTERLINE BRANDS, INC.
PROVIDES UPDATED EARNINGS GUIDANCE
JACKSONVILLE, Fla., July 11, 2005 / PRNewswire / -- Interline Brands, Inc.
(NYSE: IBI) ("Interline" or the "Company"), a national distributor and direct
marketer of maintenance, repair and operations (MRO) products, recently
announced that it had acquired Copperfield (CCS Enterprises, Inc.), a national
distributor and direct marketer of specialty ventilation and chimney maintenance
products.
The Copperfield acquisition is expected to be accretive to earnings in the
fourth quarter of 2005 and Interline Brands therefore projects pro forma net
income per diluted share for 2005 of $1.05 - $1.08 for fiscal year 2005. GAAP
net income per diluted share for fiscal year 2005 is expected to be $0.84 -
$0.87, including estimated transaction costs associated with the Company's
secondary offering announced today.
For the second quarter of 2005, the Company reaffirms its previous projection of
net income per diluted share of $0.24 - $0.26.
ABOUT INTERLINE
Interline Brands, Inc. is a leading national distributor and direct marketer
with headquarters in Jacksonville, Florida. Interline provides maintenance,
repair and operations (MRO) products to approximately 150,000 professional
contractors, facilities maintenance professionals, hardware stores, and other
customers across North America and Central America.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
The statements contained in this release which are not historical facts are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those set forth in, or
implied by, forward-looking statements. The company has tried, whenever
possible, to identify these forward-looking statements using words such as
"projects", "anticipates", "believes", "estimates", "expects", "plans,"
"intends", and similar expressions. Similarly, statements herein that describe
the company's business strategy, outlook, earnings projections, objectives,
plans, intentions or goals are also forward-looking statements. The risks and
uncertainties involving forward-looking statements include the successful
integration of the Copperfield acquisition, the failure to locate, acquire and
integrate acquisition candidates, material facilities systems disruptions and
shutdowns, the dependence on key employees and certain other risks described in
the company's Form 10-K (Commission File No. 001-32380). These statements
reflect the company's current beliefs and are based upon information currently
available to it. Be advised that developments subsequent to this release are
likely to cause these statements to become outdated with the passage of time.
The company does not currently intend, however, to update the information
provided today prior to its next earnings release.
OTHER INFORMATION
Interline has provided pro forma net income per diluted share for fiscal year
2005 to exclude the impact of certain transactions and expenses relating to
equity offerings. Pro forma net income for 2005 excludes $0.19 per share in
charges and expenses arising from a $10.3 million loss on early extinguishment
of debt related to the redemption of $70 million of the Company's 11.5% senior
subordinated notes that occurred in the first quarter of 2005 using a portion of
the Company's IPO proceeds, the interest expense of the redeemed notes and the
tax impact of the redemption. In addition, pro forma net income for 2005
excludes expenses to be incurred by Interline relating to its recently announced
secondary offering. Such expenses are expected to be $0.7 million to $1.0
million.
CONTACT: TOM TOSSAVAINEN
PHONE: 904-421-1441

text: INTERLINE BRANDS, INC.

text: Interline Brands, Inc.

text: Copperfield (CCS Enterprises, Inc.)

text: Interline Brands, Inc.


text:
EX-99.1
2
v133751_ex99-1.htm
MMC
ENERGY, INC.
26
Broadway
Suite
960
New
York,
NY 10004
(212)
977-0900
MMC
ENERGY, INC. ANNOUNCES SALE OF EQUIPMENT
New
York-
November 26, 2008-MMC Energy, Inc. (NASDAQ: MMCE) announced today that it signed
a definitive agreement to sell its membership interest in MMC Escondido II,
LLC,
(the "Membership Interest") a wholly-owned subsidiary whose only asset is an
agreement to acquire a General Electric LM6000 PC Sprint® turbine for $15.3
million to an affiliate of Wellhead Electric Company, Inc.. The Company
continues to own all other assets related to the Escondido peaking facility,
including the permit to upgrade that facility.
The
sale
of this Membership Interest will provide the Company with substantial additional
near term liquidity and avoid paying costs related to transportation, storage,
interest and taxes on the turbine. The Company agreed to acquire the turbine
from General Electric for an expected delivery in December 2008 for use at
its
Escondido Energy Upgrade Project. The Company is in the process of preparing
to
submit bids for long-term contracts for peaking power for this Upgrade Project,
which are likely to commence in 2010, and believes that the disposition of
the
turbine at this time is a better option than incurring substantial costs to
store and maintain the turbine until construction at its Escondido generating
site commences. The Company believes that there will be comparable turbines
available on a timely basis when required to begin construction. Using the
proceeds from the sale, the Company will repay its $3.57 million outstanding
equipment loan debt balance with GE Energy Financial Services associated with
this turbine, while retaining its loan facility tied to its remaining two
LM-6000 turbines on order.
The
Company expects that the two additional LM6000 turbines that the Company ordered
from General Electric for its Chula Vista Upgrade Project will be delivered
in
March 2009. The Company anticipates that it will receive permits from the
California Energy Commission for its re-powering of the Chula Vista site in
the
first quarter of 2009.
Michael
Hamilton, CEO of MMC Energy commented, "We continue to believe that our power
generation facilities in San Diego carry significant value, given the shortage
of new generation throughout the State of California. Given the lengthy
permitting process in the State of California, we are confident that significant
value has been created at our existing generating sites and intend to upgrade
the sites upon receiving long-term contracts for the output from our
facilities".
About
MMC Energy, Inc.:
The
Company acquires and actively manages electricity generating and energy
infrastructure-related assets in the United States. The Company is traded on
the
NASDAQ Global Market in the United States.
The
Company's mission is to acquire, directly or through joint ventures, a portfolio
of small to mid-size natural gas fueled electricity generating assets, generally
below 80 megawatts or "MW".
The
Company creates long-term value for its shareholders through disciplined asset
acquisitions and hands on post-acquisition asset management. The Company has
invested in electricity assets which provide essential services to key
transmission constrained markets in California, where regulatory capacity
requirements and a lack of local electricity supplies make peak electricity
generation facilities valuable.
To
date,
the Company has acquired three electricity generating assets in California,
totaling 110 MW of capacity. The Company is poised to upgrade two of these
assets, the 97 MW MMC Chula Vista Upgrade and the 48.5 MW MMC Escondido Upgrade,
both located in San Diego County, California. When completed, the upgrades
will
add an incremental 89 MWs to this transmission constrained region.
Forward
Looking Statements:
This
press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934 including anticipated events relating to
completion of the Company's current upgrade projects. Although the
forward-looking statements in this release reflect the good faith judgment
of
management, forward-looking statements are inherently subject to known and
unknown risks and uncertainties that may cause actual results to be materially
different from those discussed in these forward-looking statements including,
but not limited to, those risks described in the Company's Annual Report on Form
10-K, its most recent prospectus filed with the SEC on November 19, 2007 and
in
its other public filings. Readers are urged not to place undue reliance on
these
forward-looking statements, which speak only as of the date of this release.
The
Company undertakes no obligation to update these forward-looking statements.
Source:
MMC Energy, Inc.
Contact:
MMC
Energy Inc.
Denis
G.
Gagnon, Chief Financial Officer
(212)
977-0900
www.mmcenergy.com
BPC
Financial Marketing
Investor
Contact:
John
Baldissera
(800)
368-1217

text:
MMC
ENERGY, INC.

text:
MMC
ENERGY, INC.

text: MMC Energy, Inc.

text:
MMC Escondido II,
LLC

text: Wellhead Electric Company, Inc.

text:
Michael
Hamilton

text: MMC Energy, Inc.

text: MMC Energy, Inc.

text:
Denis
G.
Gagnon


text:
EX-99.3
12
pr.htm
PR 060409
pr.htm
PRESS
RELEASE - FOR IMMEDIATE RELEASE
June 3,
2009
SHRINK
NANOTECHNOLOGIES ACQUIRES ACCLAIMED
NANOTECHNOLOGY
BUSINESS FOR $9,000,000
Shrink
Nanotechnologies To Commercialize Nanotech Device Platform and Manufacture
Diagnostic Polystyrene Devices For Drug Discovery, DNA Research, Immunological
and Environmental Testing Assays and Other Devices Based On Metal-Enhanced
Fluorescence Nanostructures
Carlsbad,
California - Shrink Technologies, Inc. ("Shrink Technologies"), a California
corporation, has agreed to be acquired in a stock-for-stock transaction by
Shrink Nanotechnologies, Inc. (OTCBB: AUIO - News). The transaction
closed on May 29, 2009, and as a result, Shrink Technologies, Inc., a California
corporation, is now a wholly owned subsidiary of Shrink Nanotechnologies, Inc.
("Shrink"), a Delaware corporation. The transaction purchase price
was just under US $9,000,000 and called for Shrink to issue 8,888,888 Shrink
common shares, 50 Series C Preferred shares and to add one new person to the
Shrink Board of Directors. The closing price of Shrink's stock on the
date of the acquisition was $1.01 per share. Shrink has applied for a
new trading symbol with FINRA and expects to trade under a new symbol in the
coming weeks.
Commenting
on the acquisition, Shrink CEO Mark L. Baum stated, "We are pleased to have
concluded the transaction to acquire Shrink Technologies, a company with a very
promising portfolio of licensed technologies which we believe will be impactful
in a number of fast growing multi-billion dollar markets. We also
welcome to Shrink, a team of world class scientists and technology innovators
from some of our Nation's most prestigious academic
institutions. Together, we will continue the vision of Dr. Michelle
Khine as we aggressively seek to commercialize devices engineered from an
innovative manufacturing, prototyping and nano-technology development platform
called the Shrink Chip Manufacturing Solution".
"The most
impressive aspect of the technology we have purchased has been the initial
testing results we have seen for our metal-enhanced fluorescence ("MEF")
applications. In simple terms, our MEF technology is a marriage of
our rapid prototyping methods with cutting-edge advancements in
metal-fluorescence enhanced immunoassays. The mission of our MEF
Solutions Group is to develop devices based on our patent-pending technologies
to significantly enhance existing platforms across a broad spectrum of product
categories".
"Shrink's
MEF applications employ metal-based nanostructures created through Shrink's
patent-pending processes in conjunction with standard fluorescence methods to
radically enhance the ability of a diagnostic assay to detect interactions at a
level of sensitivity which we believe is unparalleled. In essence,
many of the potentially exciting interactions that are unable to be seen by
today's methods can be visualized by this new MEF technology. This
has broad implications in the fields of drug discovery, environmental sensing,
medical diagnostics and beyond".
"One
important use we believe is in the drug discovery industry. The drug
discovery process often involves the screening of hundreds of thousands of
compounds for highly specific interactions. Only compounds that
display high specificity are further investigated for potential therapeutic
benefit. With current methods, drug companies are limited by the
level of sensitivity of screening assays to detect interactions, thereby
excluding potentially groundbreaking drug candidates that escape
detection. Shrink's MEF technology, which can be integrated into
existing market-leading diagnostic systems, has the potential to identify these
missed drug interactions, allowing the drug companies to explore the therapeutic
benefit of these candidates".
"Shrink's
MEF technology can be directed towards clinical diagnostic applications as
well. Clinical diagnostic assays are at the frontline for disease
diagnosis and treatment. Doctors rely on clinical lab results to
detect the early onset of disease which better ensures the efficacy of proposed
treatments. However, many diseases are undetectable by current
diagnostic methods at onset, often times preceding symptoms and other
signs. This is why the healthcare industry has placed such a heavy
emphasis on screening and early detection; those patients that are diagnosed
earlier more often than not do better than patients that are diagnosed at later
stages. With Shrink's MEF technology coupled with next generation
diagnostic assays, earlier and more specific detection is be
possible. Instead of treating diseases, doctors can focus on
preventing them, thereby saving billions of healthcare-related costs and
increasing patient's quality of life and morbidity".
"We have
only begun to touch on the uses for the technologies we have
purchased. Beyond diagnostics, our team of product engineers has
created prototype products for a number of applications including stem cell
research and development tools and custom microfluidic chip prototyping
systems. We believe the flexible "wrinkled" substrates we make have
the ability to make solar cells more efficient "traps" for light, and our
engineers are developing biodegradable plastic lattices for the creation of
organ and nerve tissue".
"We
believe the next chapter in the history of diagnostic technologies has
begun. We live in a country that has reset its priorities and has
concluded that science and research and development of new and innovative
science can make a difference in the lives of our people and can be a
significant part of how our country provides global leadership in the coming
century. We are inspired by our opportunities and by our national
priorities, and we intend to continue to research develop our technologies and
products, and to use our vast and growing network of academic and industry
contacts to review new products and technologies that may compliment our
existing portfolio as we execute on the mission and vision of our new
company."
About Shrink
Nanotechnologies, Inc.
Shrink
represents the first start-up company from the University of California Merced,
and brings together leading scientists, business advisors and an executive team
that is dedicated to bringing its exclusively licensed technology to the
commercial marketplace. Shrink solutions, including its substrates,
devices and research tools are being designed to not only mechanically effective
in the solar energy, environmental detection, stem cell and biotechnology
markets, they are also being made from biodegradable materials, including
corn-based plastics.
Shrink
has created the Shrink Chip Manufacturing Solution™ which utilizes the unique
characteristics of Shrink Chips™. Made from a shrinkable
thermo-plastic material, Shrink Chips™ enable complex structures to be designed
at the macro-scale, while retaining the original designs on a much smaller
scale. Shrink's applications can be designed and prototyped in a few
hours and in a cost-effective manner versus conventional methods utilizing
silicon or other materials that require costly fabrication equipment and labor
intensive processes. Shrink creates features retract uniformly, to a fraction of
the original size. Because the patterned features "shrink", Shrink devices do
not require high-resolution printing which is otherwise necessary to achieve
such fine features. This flexible and elegant design and fabrication solution
reduces costs by eliminating the need for expensive clean room equipment and
vastly improves time-to-market for products in Shrink's focused market
segments.
More
information about Shrink may be found at www.ShrinkNano.com.
Forward-Looking
Statements
This news
release contains forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934 that involve risks, uncertainties and assumptions, including statements
about the markets for and uses of products described in this press release and
other technologies which Shrink Nanotechnologies, Inc. seeks to
commercialize. Actual results and the timing of events could differ
materially from those anticipated in these forward-looking statements as a
result of several factors including unanticipated delays in the completion of
the commercialization of Shrink Nanotechnologies, Inc.'s products and the market
appetite for Shrink's services. The forward-looking statements made herein speak
only as of the date of this press release and the company undertakes no
obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.
Contact:
Shrink
Nanotechnologies, Inc.
Mark L.
Baum, Esq., 760-804-8844 x205
mark@shrinknano.com

text: Shrink Technologies, Inc.

text: Shrink Technologies

text: Shrink Nanotechnologies, Inc.

text: Shrink Technologies, Inc.

text: Shrink Nanotechnologies, Inc.

text: Shrink Technologies

text:
Michelle
Khine

text:
Shrink
Nanotechnologies, Inc.

text: Shrink Nanotechnologies, Inc.

text: Shrink Nanotechnologies, Inc.

text:
Shrink
Nanotechnologies, Inc.


text:
EX-99.1
6
dex991.htm
PRESS RELEASE
Press Release
Exhibit 99.1
PRESS RELEASE
Contact: Alfred J. Novak, Novoste Corporation
Krish Suthanthiran
President and Chief Executive Officer
President
(770) 717-0904
Best Vascular, Inc.
Best Medical International, Inc.
(703) 451-2378
NOVOSTE AND BEST VASCULAR COMPLETE ASSET SALE TRANSACTION
NORCROSS, GA.-(BUSINESS WIRE)-March 9, 2006 - Novoste Corporation (NASDAQ: NOVT) and Best Vascular, Inc. (Best Vascular) jointly announced today the
completion of the sale of substantially all of the assets of Novoste's Vascular Brachytherapy (VBT) business to Best Vascular. The two companies had previously announced the transaction on October 12, 2005, and the Novoste
shareholders' meeting at which the proposal to approve the transaction was adopted was held on March 7, 2006. The consideration for the sale of the assets by Novoste to Best Vascular was the assumption by Best Vascular of various
liabilities of Novoste related to its VBT business. As part of the transaction, Novoste amended its charter to change its corporate name to "NOVT Corporation".
Krish Suthanthiran, President of Best Vascular, has commented, "We are very excited about the opportunity that exists for Best Vascular in the VBT market. The acquisition of these assets fits our strategy of
providing brachytherapy therapy products across a wide variety of clinical applications. It is of utmost importance that radiation therapy is available to cardiologists and their patients. The Novoste system is the only remaining vascular
brachytherapy product on the market and having previously supplied Cordis Corporation, a Johnson & Johnson company with VBT products, we believe we have the capability to assure the continuation of this important therapy in the cardiology
market. We remain committed to our radiation oncology customer base and look forward to serving the particular needs of the cardiology community with a therapy that has proven durable results".
Best Vascular intends to formally launch its marketing of the Novoste, BetaCath product at a special breakfast symposium on Wednesday, April 5, 2006 beginning at
7:00 a.m. The symposium will be held at the Hyatt Regency Crystal City in Arlington, Virginia in conjunction with the Cardiovascular Revascularization Therapies (CRT) meeting. Sponsored by Best Vascular, the breakfast symposium
will update the status of vascular brachytherapy and the BetaCath of Novoste for 2006 and will feature presentations on
the treatment of drug-eluting stent restenosis with vascular brachytherapy and five-year clinical follow-up data with the BetaCath system. In addition, discussions on new opportunities for your institution to re-launch the BetaCath system will also
take place.
Al Novak, President and Chief Executive Officer of Novoste, said "We are pleased that we have completed this transaction with Best
Vascular. They have the capability and interest in supplying VBT to those physicians and their patients who have a need for this technology. This transaction was in the best interests of our shareholders by allowing Novoste to be free of its major
liabilities associated with the VBT business".
About Best Vascular and Best Medical International, Inc.
Best Vascular's and Best Medical International, Inc.'s (Best Medical) corporate headquarters are located at 7643 Fullerton Road, Springfield, Virginia. Best
Vascular, an affiliate of Best Medical, was established for the purpose of focusing on the vascular brachytherapy business acquired from Novoste. Best Medical is known for its radiation seed products utilizing several different isotopes. Best
Medical also has a complete line of catheters, needles, templates and accessories, including custom-designed products. Founded in 1977, Best Medical has pioneered new ideas in brachytherapy, including vascular brachytherapy, and is a leader in the
provision of radiation seeds for use by urologists in the treatment of prostate cancer. Best Medical prides itself not only on its very successful product line, but also the ability of its staff to provide superlative service to its customers. Best
Medical's mission is to uphold its excellent reputation by consistently exceeding the expectation of those it serves in the healthcare field by developing, manufacturing and delivering cost-effective, high quality products to benefit patients
throughout the world.
About Novoste (now known as NOVT Corporation)
Novoste common stock is traded on the Nasdaq National Stock Market under the symbol NOVT. For general company information, please call (770) 717-0904 or visit
Novoste's new website at www.NOVTCorporation.com.
***

text: Krish Suthanthiran

text: Best Vascular

text: BEST VASCULAR

text: Best Vascular

text: Best Vascular

text: Novoste's Vascular Brachytherapy

text: Best Vascular

text: Best Vascular

text: Best Vascular

text: Krish Suthanthiran

text: Best Vascular

text: Best Vascular

text: Best Vascular

label: event

text: Best Vascular

text:
Best
Vascular

text: Best Vascular

text: Best Vascular

text:
Best
Vascular


text:
EX-99
2
exhibit99-1.htm
EXHIBIT 99.1 - PRESS RELEASE
Exhibit 99.1
CONTACT:
Press Inquiries
Investor Inquiries
Public Relations
Investor Relations
Sycamore Networks, Inc
Sycamore Networks, Inc.
978-250-3433
978-250-3460
scott.larson@sycamorenet.com
i
nvestor.info@sycamorenet.com
SYCAMORE NETWORKS COMPLETES ACQUISITION OF EASTERN RESEARCH
Acquisition Increases Customer Base and Expands Product Portfolio with Complementary Suite of
Carrier-Class Network Access Solutions
CHELMSFORD
, Mass., September 6, 2006 - Sycamore Networks, Inc. (NASDAQ: SCMR) today announced it has completed the acquisition of Eastern Research, Inc., an innovative provider of network access solutions for fixed line and mobile network operators worldwide. The addition of Eastern Research's field-proven products enables Sycamore to expand its customer base, increase the markets it serves, and extend its intelligent networking capabilities to a complementary suite of carrier-class access solutions.
With the close of this transaction, Sycamore offers a broad range of intelligent networking solutions that span multiple network segments, including network access, regional backhaul, and core switching sites. The Company's expanded portfolio, which now includes multiservice cross-connects, multiservice access platforms and base station access gateway solutions, enables network operators to cost-efficiently optimize service bandwidth, streamline network operations, and deploy new services while improving performance and reliability.
"As fixed line and mobile networks evolve to support a growing number of dynamic broadband services and applications, network operators will require new levels of efficiency, agility, and scalability from network access points to the optical core", said Daniel E. Smith, president and chief executive officer, Sycamore Networks. "This acqusition is a first step towards leveraging Sycamore's strengths in the core to offer our customers a more comprehensive suite of solutions optimized for the traffic driving network growth".
About Sycamore Networks
Sycamore Networks, Inc. (NASDAQ: SCMR) is a leading provider of intelligent networking solutions for fixed line and mobile network operators worldwide. From multiservice access networks to the optical core, Sycamore products enable network operators to lower overall network costs, increase operational efficiencies, and rapidly deploy new revenue-generating services. Sycamore's global customer base includes Tier 1 service providers, government agencies, and utility companies. For more information, please visit www.sycamorenet.com.
We wish to caution you that certain matters discussed in this news release constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned that actual results or events could differ materially from those stated or implied in forward-looking statements. These risks and uncertainties include, but are not limited to risks relating to (a) our ability to successfully integrate the businesses of the Company and Eastern Research, Inc., which may result in the combined company not operating as effectively and efficiently as expected; (b) our ability to achieve the expected synergies from the merger or it may take longer than expected to achieve those synergies; (c) unexpected costs or unexpected liabilities, or the effects of purchase accounting resulting from the merger may be different from our expectations; (d) the combined company may be adversely affected by future legislative,
regulatory, or tax changes as well as other economic, business and/or competitive factors; (e) the formal investigations commenced by the Securities and Exchange Commission and the U.S. Attorney's office with respect to certain stock options granted by the Company, additional actions and findings that may result from the Company's investigation into the accounting treatment for stock options, including the possible restatement of previously issued financial statements, the possible inability of the Company to file its Annual Report on Form 10-K on a timely basis and the possible issuance of a delisting notice by Nasdaq. Certain additional risks are set forth in more detail in the section entitled Factors that May Affect Future Results in the Company's most recently filed Form 10-Q, Form 10-K and the other reports filed by the Company from time to time with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future results or otherwise.

text: Sycamore Networks

text: Sycamore Networks, Inc.

text: SYCAMORE NETWORKS

text: EASTERN RESEARCH

text: Sycamore Networks, Inc.

text: Eastern Research, Inc.

text: Eastern Research

text: Sycamore

text: Sycamore

text: Daniel E. Smith

text: Sycamore Networks

text: Sycamore

text: Sycamore Networks

text: Sycamore Networks, Inc.

text: Sycamore

text: Sycamore

text: Eastern Research, Inc.


text:
EX-99.2
3
ex99_2pressrelease.htm
EXHIBIT 99.2 PRESS RELEASE
ex99_2pressrelease.htm
CANCER
THERAPEUTICS FINALIZES DEFINITIVE AGREEMENT WITH NANOTHERAPIES,
LLC.
Salt Lake City, UT
- May 27,
2009 - Cancer Therapeutics, Inc. (OTC BB: CTHP), an emerging biotechnology
business incubator with a specific emphasis on disruptive cancer treatments and
nanotechnology, announced today it has completed a formal agreement to acquire a
minority ownership share of NanoTherapies, LLC. Finalization of the
agreement comes after signing a Letter of Intent as reported in a press release
dated May 12, 2009 along with the completion of an extensive due diligence
review which was being conducted prior to the LOI.
NanoTherapies
develops life-changing therapies for cancer treatment based on an evolving set
of intellectual properties and patents derived from the exploitation of calcium
phosphate nanoparticles for therapeutic and diagnostic
applications.
The
acquisition of a 25% stake in NanoTherapies is the first acquisition completed
by Cancer Therapeutics. Chene Gardner, President and CEO of Cancer
Therapeutics, Inc. said the company is focused on generating revenue and is
interested in acquiring other companies which fit in the new business
model.
About
Cancer Therapeutics, Inc.:
Cancer
Therapeutics, Inc. is a biotechnology business incubator, with a specific
emphasis on disruptive treatments and nanotechnology. It seeks out
disruptive cancer research and technology opportunities to invest in, develop,
and commercialize. The end result will be therapies, treatments, and
pharmaceuticals targeted at more efficiently and effectively attacking
cancer. CTI seeks partners to co-develop drugs in various stages in
our pipeline.
Safe Harbor:
This letter
contains certain forward-looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended, which are intended to be covered by the safe
harbors created thereby. Investors are cautioned that all forward-looking
statements involve risks and uncertainty, including without limitation, the
ability of the Company to successfully implement its turnaround strategy,
changes in costs of raw materials, labor, and employee benefits, as well as
general market conditions, competition and pricing. Although the Company
believes that the assumptions underlying the forward-looking statements
contained herein are reasonable, any of the assumptions could be inaccurate, and
therefore, there can be no assurance that the forward-looking statements
included in this letter will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein, the
inclusion of such information should not be regarded as representation by the
Company or any other person that the objectives and plans of the Company will be
achieved. In assessing forward-looking statements included herein, readers are
urged to carefully read those statements. When used in the Annual Report on Form
10-K, the words "estimate", "anticipate", "expect", "believe", and similar
expressions are intended to be forward-looking statements.
Contact:
Investor
Relations
David
Donlin
Cervelle
Group
Phone:
407-614-5959 ext. 223

text:
CANCER
THERAPEUTICS

text:
NANOTHERAPIES,
LLC

text: Cancer Therapeutics, Inc.

text: NanoTherapies, LLC

text: NanoTherapies

text: NanoTherapies

text: Cancer Therapeutics

text: Chene Gardner

text:
Cancer
Therapeutics, Inc.

text: Cancer Therapeutics, Inc.

text:
Cancer
Therapeutics, Inc.